Health Technology Assessment (HTA)
Health Technology Assessment (HTA) is a multidisciplinary process that uses explicit methods to determine a health technology’s value for healthcare decision-making. Attitudes towards HTA vary globally, with some countries using a variety of methods and analyses and others hardly any.
A Note on the Relationship Between Age and Health-related Quality of Life Assessment
12 December 2018
A new OHE-authored paper on the relationship between age and health-related quality of life has been published in Quality of Life Research.
New Publications: Real-World Evidence for Coverage and Formulary Decisions
7 December 2018
Two articles, published in the Journal of Comparative Effectiveness Research, explore the use of real-world evidence for coverage and formulary decisions.
Presentations from ISPOR Europe 2018
23 November 2018
OHE staff recently attended the ISPOR Europe conference in Barcelona. In this blog post, we share a selection of our presentations.
OHE at ISPOR Europe 2018
7 November 2018
Meet some of the OHE team at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2018 conference in Barcelona, 10-14 November.
OHE at the ISPOR Summit on New Approaches to Value Assessment: Towards More Informed Pricing in Healthcare October, 2018
5 November 2018
OHE presented at the ISPOR Summit on New Approaches to Value Assessment: Towards More Informed Pricing in Healthcare, held October 2018.
New Publication: Advanced Therapy Medicinal Products and Health Technology Assessment
12 October 2018
A new publication in the European Journal of Health Economics identifies potential challenges of ATMPs in view of current health technology assessment (HTA) methodology and explores…
OHE Lunchtime Seminars: Steven Pearson and Janel Hanmer
4 October 2018
OHE will be hosting two lunchtime seminars in October – one on the 22nd with Steven Pearson, ICER, and another on the 31st with Janel Hanmer,…
MoCA Initiative and its Value Framework: An Opportunity to Improve Decision Making for Orphan Drugs in Europe?
18 September 2018
Orphan drugs inherently face a number of challenges in their development and value assessment. In this blog post, we describe the Mechanism of Coordinated Action (MoCA)…
Progression-free Survival as a Surrogate Outcome for Overall Survival in Oncology
4 September 2018
When should progression-free survival be used as a surrogate for overall survival in oncology? Uneven reporting of results – different definitions and methods of analysis, lack of rigour in applying methodology – make progress difficult.